公开(公告)号：US20230321042A1

公开(公告)日：2023-10-12

申请号：US18017071

申请日：2021-07-16

Applicant: PFIZER INC.

Inventor： Stephen George DANN ,  Nichol Lee Goodman MILLER ,  Todd Lee VANARSDALE

IPC: A61K31/415 ,  A61K31/565 ,  A61P35/00 ,  A61K31/4196 ,  A61K31/519

CPC classification number: A61K31/415 ,  A61K31/4196 ,  A61K31/519 ,  A61K31/565 ,  A61P35/00

Abstract: This invention relates to combination therapies for use in treating cancer, comprising a cyclin dependent kinase 2 (CDK2) inhibitor of Formula (I), as further described herein, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, optionally in further combination with an additional anti-cancer agent=.

公开(公告)号：US20250049802A1

公开(公告)日：2025-02-13

申请号：US18719456

申请日：2022-12-12

Applicant: Pfizer Inc.

Inventor： Stephen George DANN ,  Koleen Jill EISELE ,  Conglin FAN ,  Manfred KRAUS ,  Pei-Pei KUNG ,  Shikhar SHARMA ,  Hui WANG

IPC: A61K31/519 ,  A61K31/444 ,  A61K31/567 ,  A61P35/00

Abstract: The present disclosure relates to the treatment of cancer and/or cancer-associated disease. Certain aspects relate to the treatment of an individual having cancer or cancer-associated disease by administering to the individual a combination therapy of a first therapeutic agent that is an EZH2 inhibitor, a second therapeutic agent that is a CDK inhibitor, and a third therapeutic agent that is a selective estrogen receptor degrader.